Biomea Fusion, Inc. (Biomea) announced that the first patient has been dosed in its Phase I clinical trial evaluating BMF-219, the company's irreversible covalent menin inhibitor, in patients with relapsed/refractory (r/r) acute leukemias, including those with MLL1/KMT2A gene rearrangements or NPM1 mutations. The current Phase I, open-label, multi-center, dose escalation and dose expansion study is designed to assess the safety, tolerability, and pharmacokinetics/pharmacodynamics of once daily oral dosing of BMF-219 in patients with r/r acute leukemias, including subpopulations where menin inhibition is expected to provide a therapeutic benefit (e.g., patients with MLL1/KMT2A gene rearrangements or NPM1 mutations).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 USD | -5.00% |
|
+12.00% | -63.36% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.36% | 191M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+46.11% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- BMEA Stock
- News Biomea Fusion, Inc.
- Biomea Fusion, Inc. Announces First Patient Dosed